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inoCULAtion sCHeMe FoR sinGLe CHALLenGe stUDies
Preservative 0.5mL Dose Target USP <51> EP 5.1.3
Fail
None 0 NA Fail
None 0 NA Fail
Phenol 0.25% Pass Fail








Thimerosal 25µg	Hg Pass Fail
Thimerosal 50µg	Hg Pass Pass
Thimerosal 100µg	Hg Pass Pass
CoMPARison oF PReseRvAtives























13v 5mg 2PE 5°C























13v 5mg 2PE 5°C






















13v 5mg 2PE 5°C





Prevenar 13 ™ 
with 5mg dose 
2-PE
Single challenge  
EP 5.1.3 Fail Pass 
Multi-challenge Fail Pass
PRevenAR 13™ WitH 2-Pe Meets BotH sinGLe AnD  
























inoCULAtion sCHeMe FoR MULtiPLe CHALLenGe stUDies
PReseRvAtive eFFeCtiveness oF 2-Pe is Dose DePenDAnt
A minimum concentration of 3.5mg 2-PE is required to demonstrate 
consistent preservative effectiveness
Prevenar 13™ is stable in the presence of 2-PE




























































































































2-Pe is MoRe eFFeCtive tHAn tHiMeRosAL in  
inHiBitinG GRoWtH PARtiCULARLY s.AUReUs
USP <51>
























13v 50ug Thiomerosal  5°C
13v 50ug Thiomerosal  25°C
13v 5mg 2PE 5°C
















13v 50ug Thiomerosal  5°C
13v 50ug Thiomerosal  25°C
13v 5mg 2PE 5°C
















13v 50ug Thiomerosal  5°C
13v 50ug Thiomerosal  25°C
13v 5mg 2PE 5°C

















13v 50ug Thiomerosal  5°C
13v 50ug Thiomerosal  25°C
13v 5mg 2PE 5°C
13v 5mg 2PE 25°C
2-Pe is MoRe eFFeCtive tHAn tHiMeRosAL 
in MULti CHALLenGe test





None 0 Fail Fail
Thimerosal	
reference 50µg	Hg Fail Pass
Thimerosal	
reference 25µg	Hg Fail Fail
Site	Control 50µg	Hg Fail Pass
2-PE 5.0mg Pass Pass
2-PE/0.1mg	
Formalin 7.5mg Pass Pass
				EP	criteria	5.1.3	Criteria	“B”


























Representative stability data with 5mg 2-PE
LonG teRM stABiLitY oF PRevenAR 13™ ContAininG 2-Pe
Representative data demonstrates long term stability measured as total 
antigenicity of each individual serotype in Prevenar 13™.
Similar stability was observed with formulations containing  2-PE 
concentration ranging from 3.5 and 7.5mg per dose for total antigenicity, 
protein, pH and appearance
Agitation stress studies demonstrated compatibility with chosen  
vial/stoppers






























































LonG teRM stABiLitY oF 2-Pe
2-PE in a Prevenar 13™ formulation is stable for 2.5 years at 2-80C
PReseRvAtive eFFeCtiveness is MAintAineD   
AFteR stoRAGe oF PRevenAR 13™ WitH 2-Pe
Formulations consistently meet the preservative effectiveness criteria

































•	 “Pneumococcal	vaccines.	WHO	position	paper”.	Relevé épidémiologique hebdomadaire / Section d’hygiène du Secrétariat 










	 In	The European Pharmacopoeia	published	by	the	Directorate	for	the	Quality	of	Medicines	&	HealthCare	of	the	Council	of	
	 Europe	(EDQM),	Strasbourg	Cedex,	France,	pp.	5129	-5130.
•	 United	States	Pharmacopoeia	32,	Rockville	(MD)	Chapter	51	(2009).
•	 http://www.who.int/wer/pdf/1999/wer/7423.pdf
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